Work

A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies

Year: 2007

Type: article

Study design: Clinical Trial

Source: Molecular Cancer Therapeutics

Authors: Geoffrey I. Shapiro, E. Heath, Lisa Malburg, Bruce J. Dezube, Dale Miles, Harold Keer, Andrew Xu, Theresa Laeder, Patricia LoRusso

Institutions: Massachusetts General Hospital, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2278176381

FWCI: 0.719

Cites:

Cited by: 10

Related to: 20